Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years

Detalles Bibliográficos
Autores principales: Olliaro, Piero L., Kuesel, Annette C., Halleux, Christine M., Sullivan, Mark, Reeder, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Viewpoints
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237288/
https://www.ncbi.nlm.nih.gov/pubmed/30439940
http://dx.doi.org/10.1371/journal.pntd.0006837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237288/
https://www.ncbi.nlm.nih.gov/pubmed/30439940
http://dx.doi.org/10.1371/journal.pntd.0006837

Ejemplares similares